Thursday, June 12, 2014 12:47:18 PM
Conversely, it’s not uncommon for disappointing clinical data to cause a company’s valuation to crumble in the blink of an eye. Take a look at what happened on Wednesday to Orexigen Therapeutics (OREX) or in the past few months as Prana Biotechnology (PRAN) shares were scalped by about 75 percent in two days late in March or the valuation of Athersys (ATHX) getting halved late in April on disappointing trial data.
http://www.equities.com/editors-desk/stocks/healthcare/understanding-impact-clinical-trials-on-shareholder-value
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM